What is a Mounjaro Weight Loss Pen?
Mounjaro is a prescription-only, self-administered injectable medication designed to aid in weight loss. It contains tirzepatide, a peptide that works by regulating blood sugar levels and energy balance, thereby reducing appetite and cravings. Targeting specific pathways in the brain, it promotes satiety, helping individuals feel fuller for longer and mitigating hunger, resulting in significant weight loss when used in conjunction with a calorie-controlled diet and increased physical activity. Clinical studies have demonstrated that it induces weight loss beyond the effects of diet and exercise alone.
Who is Mounjaro for?
It is intended for adults aged 18 to 74 who meet the following criteria:
- Prior Weight Management Attempts: Individuals who have not attained substantial weight loss despite adherence to a supervised diet, behavioural modifications, and increased physical activity.
- Body Mass Index (BMI) Criteria:
– A BMI of 30 kg/m² or higher, or
– A BMI of 27 kg/m² or higher with at least one weight-related health condition, including:
- – Hypertension
- – Dyslipidemia (high cholesterol)
- – Obstructive sleep apnea
- – Type 2 diabetes
It is not recommended for individuals with a history of pancreatitis, or type 1 diabetes, or individuals under the age of 18, as its safety and efficacy have not been established in these populations.
Included in Your Order:
- – 1 x Mounjaro pen
- – 4 x Needles
- – 1 x Sharps bin (for safe disposal)
- – 8 x Pre-injection wipes
Usage Instructions:
The recommended starting dose is 2.5 mg subcutaneously once a week for the first 4 weeks (28 days). It is compatible with any Glucorx Finepoint or GlucoRx Carepoint needles, which are included in each order. This dose is intended for treatment initiation and is not designed to manage glycemic control. After 4 weeks, the dose may be escalated to 5 mg administered weekly.
Ingredients:
Each 2.5 mg dose contains tirzepatide (2.5 mg in 0.6 mL solution), along with sodium phosphate dibasic heptahydrate, sodium chloride, concentrated hydrochloric acid, sodium hydroxide (for pH adjustment), and water for injection.
Administration Guidelines:
- Before initiating treatment, review the instructions for use (IFU) for guidance on proper administration.
- It can be administered at any time of day, with or without food.
- Injection sites include the abdomen, thigh, or upper arm. Rotate injection sites with each dose.
- Visually inspect your dose before use. The solution should be clear and colourless to slightly yellow. Do not use it if the solution is discoloured or contains particles.
Contraindications:
It is contraindicated in patients with:
- – A personal or family history of medullary thyroid carcinoma (MTC) or those with Multiple Endocrine Neoplasia syndrome type 2.
- – Known hypersensitivity to tirzepatide or any of its excipients.
Precautions and Warnings:
– Injection Site: Injection should be administered in the abdomen, thigh, or upper arm. The injection site and timing may vary without requiring dose adjustments.
– Missed Dose: If a dose is missed and it has been no more than 4 days, inject the missed dose as soon as possible and continue with the next dose on the scheduled day. If more than 4 days have passed, skip the missed dose and resume the regular dosing schedule.
– Change of Injection Day: The day of weekly administration can be changed as long as the interval between two doses is at least 3 days (≥72 hours).
– Storage: Store it in a refrigerator (2°C – 8°C). Do not freeze. Keep it in the original packaging to protect it from light. It may be stored unrefrigerated for up to 21 cumulative days at temperatures not exceeding 30°C. After this period, the pre-filled pen must be discarded.
– Acute Pancreatitis Risk: Caution is advised for patients with a history of pancreatitis. Discontinue use if symptoms of pancreatitis occur.
– Hypoglycemia Risk in Type 2 Diabetes: Monitor for hypoglycemia when using Mounjaro in combination with insulin or insulin secretagogues. Dose adjustments of insulin or other medications may be necessary.
– Gastrointestinal Disorders: Use with caution in patients with severe gastrointestinal conditions, such as gastroparesis.
– Diabetic Retinopathy: Exercise caution in patients with diabetic retinopathy and ensure appropriate monitoring.
– Pregnancy and Lactation: It is not recommended during pregnancy due to insufficient data. It is unknown whether Mounjaro is excreted in human milk, so the potential risks should be weighed against the benefits.
– Effects on Driving and Operating Machinery: It is unlikely to impair the ability to drive or operate machinery, but caution is advised when used with insulin or sulfonylurea to prevent hypoglycemia.
Adverse Effects: Potential side effects include, but are not limited to:
- – Very Common: Hypersensitivity reactions, hypoglycemia (especially with insulin or sulfonylureas), and dizziness.
- – Common: Nausea, diarrhea, vomiting, constipation, and fatigue.
- – Uncommon: Hair loss, abdominal pain, and acute pancreatitis.
For a complete list of potential side effects, please consult your healthcare provider.
*Note:
- – (1) Dose-dependent
- – (2) More common in certain populations
- – Fatigue may encompass both general exhaustion and physical weakness.
Product Reviews
There are no reviews yet.